Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Prev Res (Phila). 2020 May 20;13(8):661–672. doi: 10.1158/1940-6207.CAPR-20-0054

Figure 1.

Figure 1.

SFN treatment induces LAMP2 expression in human prostate cancer cells. A, Chemical structure of SFN. B, Viability of PC-3 and 22Rv1 cells after 24-hour of treatment with DMSO or the indicated doses of SFN. Results shown are mean ± SD (n=3). Experiment was repeated with comparable results. *Statistically significant compared with DMSO-treated control by one-way ANOVA with Dunnett’s adjustment (P<0.05). C, qRT-PCR analysis for LAMP2 mRNA level in PC-3 and 22Rv1 cells treated with DMSO or the indicated doses of SFN for 6 hours. Results shown are mean ± SD (n=3). *Statistically significant compared with DMSO-treated control by one-way ANOVA with Dunnett’s adjustment (P<0.05). Experiment was repeated with comparable results. D, Immunoblotting for LAMP2 and β-Actin proteins using lysates from PC-3 and 22Rv1 cells after treatment with DMSO or the indicated doses of SFN for specified time points. Experiment was done twice and the results were generally consistent. E, Representative immunofluorescence microscopy images for LAMP2 (red), DAPI (blue), and LysoTracker (Lyso, green) in PC-3 and 22Rv1 cells treated with DMSO or the indicated doses of SFN for 9 hours. Experiment was repeated with generally comparable results.